Integran Technologies Inc. on February 7 announced its first issued patent pertaining to the use of its metallurgical nano-technologies for enhancing the durability, reliability and longevity of biomedical implants. US Patent 8,273,117 discloses a "Low Texture Quasi-Isotropic Stent" having superior mechanical properties for use in the treatment of coronary artery disease. The innovation focuses in improving stent performance by optimizing the implant metal microstructure using Integran’s grain boundary engineering technology.
“We are currently developing several biomedical applications for our nano-engineered materials, and we are very pleased that the US Patent & Trademark Office has recognized the applicability of our novel grain boundary engineering (GBE®) nano-technology to conventional metallic implant alloys,” said Gino Palumbo, CEO of Integran.
For more information, please visit www.integran.com.
